ProfileGDS5678 / 1458814_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 37% 38% 38% 39% 38% 38% 37% 37% 38% 38% 37% 38% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.886537
GSM967853U87-EV human glioblastoma xenograft - Control 22.8618338
GSM967854U87-EV human glioblastoma xenograft - Control 32.8637938
GSM967855U87-EV human glioblastoma xenograft - Control 42.8279439
GSM967856U87-EV human glioblastoma xenograft - Control 52.8185938
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9653738
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9007337
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8418937
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8408338
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8493538
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8456337
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8333838
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8550437
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8500637